Clinical Trial Update: A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency [Phase 2]

View source ↗

Summary

Phase 2 trial of LY2606368 (Prexasertib) in patients with solid tumors exhibiting replicative stress or homologous recombination deficiency has completed with p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancers

Drugs mentioned

• LY2606368 (prexasertib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Advanced Cancers | Phase 2 | Status: COMPLETED | Results posted: 2022-02-09